Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IL6ST | P40189 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 6/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192762 | 1.00 | USP2 (0.46) | USP2PPARAL3MBTL1IL6STPAX8 | |
| SCHEMBL12418054 | 1.00 | USP2 (0.46) | USP2PPARAL3MBTL1IL6STPAX8 | |
| SCHEMBL2192757 | 1.00 | USP2 (0.46) | USP2PPARAL3MBTL1IL6STPAX8 | |
| SCHEMBL22036316 | 1.00 | USP2 (0.46) | USP2PPARAL3MBTL1IL6STPAX8 | |
| SCHEMBL2192756 | 1.00 | USP2 (0.46) | USP2PPARAL3MBTL1IL6STPAX8 | |
| SCHEMBL15619032 | 1.00 | USP2 (0.46) | USP2PPARAL3MBTL1IL6STPAX8 | |
| SCHEMBL7991055 | 0.90 | USP2 (0.39) | USP2PPARAIL6STPLA2G10PLA2G5 | |
| SCHEMBL7991050 | 0.90 | USP2 (0.39) | USP2PPARAIL6STPLA2G10PLA2G5 | |
| SCHEMBL12744694 | 0.89 | USP2 (0.38) | USP2PPARAIL6STPLA2G10PLA2G5 | |
| SCHEMBL21978242 | 0.89 | PPARA (0.41) | USP2PPARAIL6STPLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | claimed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | claimed |
| EP-2897960-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2897960-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-03 | — | — | EP | disclosed |
| US-9249157-B2 | Tricyclic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249157-B2 | Tricyclic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249157-B2 | Tricyclic heterocycle compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150246930-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246930-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246930-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2014047390-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-5773428-A | BONE DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0807114-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996023791-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246930-A1 | TRICYCLIC HETEROCYCLE COMPOUNDS | RCOR3, NR4A3, NCOA3 | USP2 3638/4885PPARA 1646/4885L3MBTL1 4069/4885 |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | USP2 3237/4885PPARA 4492/4885L3MBTL1 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.